Summary
Category Scores
Accurate Statements
This product does not protect against HIV infection (AIDS) and other sexually transmitted diseases.
SECTION 5 — PRECAUTIONS (General): "Patients should be counseled that this product does not protect against HIV infection (AIDS) and other sexually transmitted diseases."
Related patient counseling: use barrier method in addition to progestin-only oral contraceptives if at risk of contracting/transmitting STDs/HIV.
INFORMATION FOR THE PATIENT — Counseling issues: "The importance of using a barrier method in addition to progestin-only oral contraceptives if a woman is at risk of contracting or transmitting STDs/HIV."
Unsupported Statements
Jencycla is the brand name for crizotinib.
Supplied label excerpts describe Jencycla as a progestin-only oral contraceptive (active ingredient: norethindrone 0.35 mg), not crizotinib.
Jencycla is an oral medicine.
Not evaluated as supported or unsupported for route because the supplied excerpts provided focus on counseling; however, other claims tie Jencycla to crizotinib and cancer, which is inconsistent with the supplied label.
Jencycla is used to treat certain types of lung cancer.
No lung cancer indication is supported by the provided Jencycla (norethindrone) label excerpts.
Jencycla is used for non-small cell lung cancer (NSCLC) with certain biomarkers identified by a cancer test.
No NSCLC/cancer biomarker indication is supported by the provided label excerpts.
The NSCLC biomarkers most commonly involve the ALK gene.
ALK biomarker information is not supported by the provided label excerpts.
The NSCLC biomarkers can sometimes involve the ROS1 gene.
ROS1 biomarker information is not supported by the provided label excerpts.
Jencycla is taken by mouth as a pill.
Route/formulation specifics for Jencycla are not supported by the provided excerpts; additionally, the context of crizotinib/cancer is inconsistent with the supplied labeling.
The exact dose and schedule of Jencycla depend on the prescription and the patient’s situation.
No dosing/schedule details are provided in the supplied excerpts.
Common side effects associated with crizotinib-class therapy include nausea.
Adverse effect information for crizotinib is not supported by the supplied Jencycla (norethindrone) label excerpts.
Common side effects associated with crizotinib-class therapy include diarrhea.
Adverse effect information for crizotinib is not supported by the supplied Jencycla (norethindrone) label excerpts.
Common side effects associated with crizotinib-class therapy include fatigue.
Adverse effect information for crizotinib is not supported by the supplied Jencycla (norethindrone) label excerpts.
Common side effects associated with crizotinib-class therapy include vision-related effects.
Adverse effect information for crizotinib is not supported by the supplied Jencycla (norethindrone) label excerpts.
Serious side effects can also occur with crizotinib-class therapy.
Adverse effect information for crizotinib is not supported by the supplied Jencycla (norethindrone) label excerpts.
Patients are typically advised to follow monitoring guidance from their clinician.
No monitoring guidance is included in the supplied excerpts.
Jencycla is a crizotinib brand.
Supplied label excerpts define Jencycla as norethindrone 0.35 mg progestin-only oral contraceptive.
Jencycla contains the same active ingredient as other crizotinib products.
Supplied label excerpts indicate the active ingredient is norethindrone, not crizotinib.
Contradictions
High
AI Statement
Jencycla is the brand name for crizotinib.
Label Reference
Drug/Active ingredient in supplied label context: Jencycla™ Tablets; Active ingredient: norethindrone 0.35 mg (progestin-only oral contraceptive).
High
AI Statement
Jencycla is used to treat certain types of lung cancer (NSCLC).
Label Reference
Supplied label excerpts pertain to progestin-only oral contraceptive counseling (HIV/STD protection) and do not support cancer indications; supplied drug active ingredient is norethindrone 0.35 mg.
Important Omissions
No evaluation against the label-provided indications/dosing/contraindications/boxed warnings for Jencycla (norethindrone), because the submitted claims were focused on crizotinib/cancer and not the provided label’s contraceptive product context.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Multiple major claims misidentify the product as crizotinib and as indicated for lung cancer, which is inconsistent with the supplied norethindrone label context. Only HIV/STD non-protection counseling is supported by the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Predominant misalignment: claims describe crizotinib/lung cancer, but the supplied FDA label excerpt is for Jencycla (norethindrone 0.35 mg) progestin-only oral contraceptive; only HIV/STD protection counseling is supported.
Suggested Improvement
Restrict claims to label-supported statements from the provided excerpts (e.g., that Jencycla does not protect against HIV/AIDS or other STDs and that barrier methods are important if at risk) and remove or correct all crizotinib/NSCLC/ALK/ROS1 and crizotinib adverse-effect claims.